Radiogenomics Explained

The term radiogenomics is used in two contexts: either to refer to the study of genetic variation associated with response to radiation (radiation genomics) or to refer to the correlation between cancer imaging features and gene expression (imaging genomics).

Radiation genomics

In radiation genomics, radiogenomics is used to refer to the study of genetic variation associated with response to radiation therapy. Genetic variation, such as single nucleotide polymorphisms, is studied in relation to a cancer patient's risk of developing toxicity following radiation therapy.[1] [2] [3] It is also used in the context of studying the genomics of tumor response to radiation therapy.[4] [5]

The term radiogenomics was coined in 2002 by Andreassen et al. (2002)[6] as an analogy to pharmacogenomics, which studies the genetic variation associated with drug responses. See also West et al. (2005)[7] and Bentzen (2006).[8]

The Radiogenomics Consortium

In 2009,[9] [10] a Radiogenomics Consortium (RGC) was established to facilitate and promote multi-centre collaboration of researchers linking genetic variants with response to radiation therapy. The Radiogenomics Consortium (http://epi.grants.cancer.gov/radiogenomics/) is a Cancer Epidemiology Consortium supported by the Epidemiology and Genetics Research Program of the National Cancer Institute of the National Institutes of Health.[11] RGC researchers have completed numerous clinical studies that identified genetic variants associated with radiation toxicities in patients with prostate, breast, lung, head and neck, and other cancers.

Past meetings

Imaging genomics [12]

Radiological images are used to diagnose disease on a large scale: tissue imaging correlates with tissue pathology. The addition of genomic data including DNA microarrays, miRNA, RNA-Seq allows new correlations to be made between cellular genomics and tissue-scale imaging.

See also

Further reading

Notes and References

  1. Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, Burnet NG, Chang-Claude J, Coles CE, Gutiérrez-Enríquez S, Fuentes-Raspall MJ, Alonso-Muñoz MC, Kerns S, Raabe A, Symonds RP, Seibold P, Talbot CJ, Wenz F, Wilkinson J, Yarnold J, Dunning AM, Rosenstein BS, West CM, Bentzen SM. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity.. Radiother Oncol. 2012. 105. 3. 289–95. 23199655. 10.1016/j.radonc.2012.10.017. 3593101.
  2. Barnett GC, Coles CE, Elliott RM, Baynes C, Luccarini C, Conroy D, Wilkinson JS, Tyrer J, Misra V, Platte R, Gulliford SL, Sydes MR, Hall E, Bentzen SM, Dearnaley DP, Burnet NG, Pharoah PD, Dunning AM, West CM. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.. Lancet Oncol. 2012. 13. 1. 65–77. 22169268. 10.1016/S1470-2045(11)70302-3. free.
  3. Talbot CJ, Tanteles GA, Barnett GC, Burnet NG, Chang-Claude J, Coles CE, Davidson S, Dunning AM, Mills J, Murray RJ, Popanda O, Seibold P, West CM, Yarnold JR, Symonds RP. A replicated association between polymorphisms near TNFα and risk for adverse reactions to radiotherapy.. Br J Cancer. 2012. 107. 4. 748–53. 22767148. 10.1038/bjc.2012.290. 3419947.
  4. Das. AK. Bell MH . Nirodi CS . Story MD . Minna JD . Radiogenomics predicting tumor responses to radiotherapy in lung cancer.. Sem Radiat Oncol. 2010. 20. 3. 149–55. 20685577. 10.1016/j.semradonc.2010.01.002 . 2917342.
  5. Yard. Brian D.. Adams. Drew J.. Chie. Eui Kyu. Tamayo. Pablo. Battaglia. Jessica S.. Gopal. Priyanka. Rogacki. Kevin. Pearson. Bradley E.. Phillips. James. 2016-04-25. A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nature Communications. 7. 11428. 10.1038/ncomms11428. 2041-1723. 4848553. 27109210. 2016NatCo...711428Y.
  6. Andreassen. CN. Alsner J . Overgaard J . Does variability in normal tissue reactions after radiotherapy have a genetic basis--where and how to look for it?. Radiother Oncol. 2002. 64. 2. 131–40. 12242122. 10.1016/s0167-8140(02)00154-8.
  7. West CM, McKay MJ, Hölscher T, Baumann M, Stratford IJ, Bristow RG, Iwakawa M, Imai T, Zingde SM, Anscher MS, Bourhis J, Begg AC, Haustermans K, Bentzen SM, Hendry JH. Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting.. Int J Radiat Oncol Biol Phys. 2005. 62. 5. 1264–73. 16029781. 10.1016/j.ijrobp.2005.05.001.
  8. Bentzen. SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology.. Nat Rev Cancer. 2006. 6. 9. 702–13. 16929324. 10.1038/nrc1950. 1190053.
  9. West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, Bentzen S, Burnet N, Chang-Claude J, Chuang E, Coles C, De Ruyck K, De Ruysscher D, Dunning A, Elliott R, Fachal L, Hall J, Haustermans K, Herskind C, Hoelscher T, Imai T, Iwakawa M, Jones D, Kulich C, ((EQUAL-ESTRO)), Langendijk JH, O'Neils P, Ozsahin M, Parliament M, Polanski A, Rosenstein B, Seminara D, Symonds P, Talbot C, Thierens H, Vega A, West C, Yarnold J . Establishment of a Radiogenomics Consortium . International Journal of Radiation Oncology, Biology, Physics . 2010 . 76 . 5 . 1295–1296 . 20338472 . 10.1016/j.ijrobp.2009.12.017.
  10. West. C. Rosenstein BS . Radiother Oncol. 2010. 94. 1. 117–8. 20074824. 10.1016/j.radonc.2009.12.007. Establishment of a radiogenomics consortium.
  11. Web site: National Cancer Institute of Health - Epidemiology and Genomics Research Program.
  12. [Radiomics]

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Radiogenomics".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.